NCT07331935 Efficacy of Topical Coenzyme Q10 and Curcumin for Oral Leukoplakia Treatment
| NCT ID | NCT07331935 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alexandria University |
| Condition | Oral Leukoplakia |
| Study Type | INTERVENTIONAL |
| Enrollment | 34 participants |
| Start Date | 2025-11-25 |
| Primary Completion | 2026-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 34 participants in total. It began in 2025-11-25 with a primary completion date of 2026-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Oral leukoplakia (OL) is recognized as the most common potentially malignant disorder of the oral mucosa. The pathogenesis of OL is complex and multifactorial, with oxidative stress playing a central role. Topical antioxidants have gained attention as therapeutic options to help stabilize lesions and potentially prevent malignant transformation. Both CoQ10 and curcumin have demonstrated a clinical success as strong antioxidants showing their capacity to reduce the lesion size and to stabilize the disease, ultimately preventing progression into oral malignancy. Aim: This study aims to clinically and biochemically assess the effectiveness of topical Coenzyme Q10 and Curcumin in the management of homogeneous oral leukoplakia.
Eligibility Criteria
Inclusion Criteria: * Clinically and histologically diagnosed with homogeneous oral leukoplakia not indicated for surgical excision . * Lesions accessible for topical application. * Willing to sign informed consent and comply with study instructions and return to follow up Exclusion Criteria: * Moderate-to-severe dysplasia, carcinoma in situ, or invasive oral cancer. * Presence of any visible oral lesions except for oral leukoplakia. * Active periodontal diseases as this can confound salivary biomarkers. * Significant systemic illness or immunosuppression. * Patients who have taken systemic or topical antioxidant supplements within the last four weeks will be excluded to avoid confounding effects on salivary biomarkers. * Pregnant and lactating women will be excluded due to hormonal changes that may alter oxidative stress and ethical considerations. * Patients unwilling or unable to comply with study requirements.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07331935 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Oral Leukoplakia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07331935 currently recruiting?
Yes, NCT07331935 is actively recruiting participants. Contact the research team at tasneemsleem63@gmail.com for enrollment information.
Where is the NCT07331935 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT07331935 clinical trial?
NCT07331935 is sponsored by Alexandria University. The trial plans to enroll 34 participants.